Autologous Nanofat Injection for Treatment of Stable Vitiligo

This randomized, split-site, within-participant controlled clinical study evaluated the efficacy and safety of a single session of autologous nanofat injection as an adjunct to narrowband ultraviolet B (NB-UVB) phototherapy in 20 adult patients with stable vitiligo. In each participant, one vitiligo site received autologous nanofat injection followed by NB-UVB phototherapy three times weekly for 3 months, while a comparable site received NB-UVB phototherapy alone. Treatment response was assessed by standardized photography performed by a blinded dermatologist, with evaluation of the onset and percentage of repigmentation, patient satisfaction, and treatment-related adverse effects.

Inclusion Criteria: * Adults aged 18 years or older. * Male or female patients. * Patients with clinically diagnosed stable vitiligo. * Presence of comparable vitiligo sites suitable for the split-site study design. * Ability to undergo autologous nanofat harvesting and injection. * Ability and willingness to undergo NB-UVB phototherapy three times weekly for 3 months. * Ability to comply with study follow-up and assessment procedures. * Provision of written informed consent. Exclusion Criteria: * Active or progressive vitiligo. * Active infection or inflammation at the treatment sites. * Significant uncontrolled systemic disease that could interfere with treatment or assessment. * Contraindication to NB-UVB phototherapy. * Contraindication to the nanofat harvesting or injection procedure. * Pregnancy or breastfeeding, if this was an exclusion criterion in your protocol. * Previous treatment of the selected study sites that could interfere with assessment. * Inability to comply with the study protocol or follow-up. * Any condition considered by the investigator to interfere with the safety or assessment of the study.